2. Search Result
Search Result
Results for "

Positive allosteric modulator of α7 nAChR

" in MedChemExpress (MCE) Product Catalog:
Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-12152
    PNU-120596
    1 Publications Verification

    NSC 216666

    		 nAChR Neurological Disease Inflammation/Immunology
    PNU-120596 (NSC 216666) is a potent and selective α7 nAChR positive allosteric modulator (PMA) that can cross the blood-brain barrier, with an EC50 of 216 nM. PNU-120596 is inactive against α4β2, α3β4, and α9α10 nAChRs. PNU-120596 has the potential for psychiatric and neurological disorders research .
    PNU-120596
  • HY-12150
    CCMI
    1 Publications Verification

    AVL-3288; UCI-4083

    		 nAChR Neurological Disease
    CCMI (AVL-3288) is a potent and selective α7 nAChR-positive allosteric modulator, does not bind to or activate α7 nAChRs via the orthosteric site, and causes significant positive modulation of agonist-induced currents at α7 nAChRs. CCMI has potential in CNS diseases with cognitive dysfunction .
    CCMI
  • HY-12151
    NS 1738

    NSC 213859

    		 nAChR Neurological Disease
    NS 1738 (NSC 213859) is a novel positive allosteric modulator of the α7 nAChR, with respect to positive modulation of α7 nAChR (EC50=3.4 μM in oocyte experiments).
    NS 1738
  • HY-107682
    TQS

    		nAChR Neurological Disease Inflammation/Immunology
    TQS is a α7 nicotinic acetylcholine receptor (nAChR) positive allosteric modulator. TQS can be used for the research of neuroinflammatory pain .
    TQS
  • HY-128575
    BNC375

    		nAChR Neurological Disease
    BNC375 is a potent, selective, and orally available type I positive allosteric modulator of α7 nAChRs with an EC50 of 1.9 μM. BNC375 exhibits good CNS-agent like properties and clinical candidate potential. .
    BNC375
  • HY-12149
    A-867744

    		nAChR Neurological Disease
    A-867744 is a highly potent and selective type II positive allosteric modulator (PAM) of the alpha7 nicotinic acetylcholine receptors (nAChR) with an EC50 of 1.0 μM .
    A-867744
  • HY-117611
    GAT107

    		nAChR Neurological Disease
    GAT107 (compound 1b) is a potent α7 nAChR ago-PAMs (positive allosteric modulators) .
    GAT107
  • HY-182694
    α7 nAChR Modulator-4

    		nAChR Neurological Disease
    α7 nAChR Modulator-4 is a positive allosteric modulator of α7 nAChR, with an EC50 of 910 nM. α7 nAChR Modulator-4 interacts with α7 nAChR to trigger downstream effects associated with inflammatory regulation. α7 nAChR Modulator-4 can be used in the research of Alzheimer's disease, Parkinson's disease and schizophrenia .
    α7 nAChR Modulator-4
  • HY-160529
    α7 nAChR Modulator-2

    		nAChR Neurological Disease
    α7 nAChR Modulator-2 (Compound 7b) is a α7 nAChR positive allosteric modulator (PAM) with an EC50 of 2.1 μM. α7 nAChR Modulator-2 can be used for the research of cognitive disorders .
    α7 nAChR Modulator-2
  • HY-157958
    α7 nAChR Modulator-3

    		nAChR Neurological Disease
    α7 nAChR modulator-3 (Compound 6p) is a α7 nAChR positive allosteric Modulator with a IC50 value of 1.3 μM. α7 nAChR Modulator-3 can be used to inhibit auditory gating defects in a mouse schizophrenic model .
    α7 nAChR Modulator-3
  • HY-12153
    JNJ-1930942

    		Cholinesterase (ChE) Neurological Disease
    JNJ-1930942 is a selective and blood-brain barrier (BBB) penetrant α(7) nAChR positive allosteric modulator.JNJ-1930942 enhances the Choline (HY-B0282)-evoked rise in intracellular Ca 2+ levels and neurotransmission at hippocampal dentate gyrus synapses. JNJ-1930942 reverses the naturally occurring sensory gating deficit in DBA/2 mice .
    JNJ-1930942
  • HY-180400
    PAM-2

    		nAChR Calcium Channel Neurological Disease
    PAM-2 is a potent, orally active, CNS-penetrant selective α7 nAChR positive allosteric modulator (human α7 nAChR EC50: 39 μM, rat α7 nAChR EC50: 12 μM) with anti-nociceptive and anti-inflammatory activity. PAM-2 exhibits selectivity over α9α10 nAChR (IC50 = 174 μM) and CaV2.2 channel (IC50 = 89 μM). PAM-2 decreases Streptozotocin (STZ) (HY-13753)- and Oxaliplatin (HY-17371)-inducned nuroparhic pain in mice by α7 nAChR potentiation. PAM-2 can be used for the research of neuropathic pain .
    PAM-2
  • HY-179621
    EQ-04

    		Cholinesterase (ChE) Amyloid-β Neurological Disease
    EQ-04 is a highly selective positive allosteric modulator (PAM) of α7 nAChR. EQ-04 has no direct inhibitory activity on AChE and BChE. EQ-04 inhibits Aβ aggregation. EQ-04 has safe cytotoxicity and potent neuroprotective activity. EQ-04 can be used for the study of Alzheimer's disease.
    EQ-04
  • HY-182707
    JWX-A0108

    		nAChR Interleukin Related TNF Receptor NF-κB Neurological Disease
    JWX-A0108 is a selective human α7 nAChR positive allosteric modulator with an EC50 of 4.35 μM. JWX-A0108 potentiates α7 nAChR currents only in the presence of acetylcholine, with no direct activating effect or alteration of desensitization. JWX-A0108 enhances hippocampal GABAergic synaptic transmission by increasing spontaneous inhibitory postsynaptic currents. JWX-A0108 reduces the brain expression levels of IL-1β, TNF-α, and IL-6 by blocking the NF-κB signaling pathway, and reduces microglial activation by downregulating Iba1. JWX-A0108 effectively improves cognitive deficits, neuroinflammation, and hippocampal neuronal damage in mouse models of schizophrenia and Alzheimer's disease. JWX-A0108 can be used for research related to schizophrenia and Alzheimer's disease .
    JWX-A0108

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: